GLP1R and type 2 diabetes mellitus: The GRAVITAS (GLP-1 Receptor Agonist interVentIon for poor responders after bariAtric Surgery) randomized controlled trial [177], demonstrated that in individuals with persistent or recurrent T2D after RYGB or SG, use of 1.8 mg liraglutide once daily in combination with lifestyle advice and support for 6 months reduced HbA1c by 1.2% and led to an additional weight loss of 4.2 kg compared to placebo [177].